Botulinum Toxin—What Urologic Uses Does the Data Support?
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Botulinum toxin-A (BTX-A) is well established in the management of various aspects of lower urinary tract dysfunction (LUTD). One formulation, OnabotulinumtoxinA has recently been licensed in many parts of the world for use in neurogenic detrusor overactivity (NDO), and in the US for idiopathic overactive bladder (OAB), in patient’s refractory to antimuscarinics. This review article looks at recent clinical publications that examine the use of BTX-A for the treatment of LUTD with a focus on OAB, detrusor overactivity (DO), benign prostatic hyperplasia (BPH) and Painful bladder syndrome / interstitial cystitis (PBS / IC). A literature review was conducted using the PubMed database and studies that were published within the time frame of January 2011 to present were included. Large randomised placebo controlled trials and a pooled analysis of patients with multiple sclerosis / spinal cord injury and NDO has suggested that BTX-A improved urinary incontinence (UI) episodes, urodynamic parameters and QoL in these patients. 200 U of OnabotulinumtoxinA appeared equivalent to 300 U. In patients with OAB, lower doses of 100 U OnabotulinumtoxinA, appear efficacious and with an acceptable adverse event profile. In one large phase III trial, de novo clean intermittent catheterisation rates were 6.1 %. Repeated injections in DO appear efficacious. Results from BPH studies are mixed, and the largest randomised study in this setting has shown significant improvements in a number of parameters for a variety of OnabotulinumtoxinA doses, but none of the doses were statistically better than placebo. Few studies have been conducted in PBS / IC and larger scale randomised placebo controlled trials are required to validate its use in this setting.
- Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213–40. CrossRef
- Lucas MG, Bosch RJ, Burkhard FC, Cruz F, Madden TB, Nambiar AK, et al. EAU guidelines on surgical treatment of urinary incontinence. Eur Urol. 2012;62(6):1118–29. CrossRef
- • Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50. Large phase III RCT in NDO pts with MS and SCI showing good efficacy for 200 and 300 U OnabotulinumtoxinA.. CrossRef
- • Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase III efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–9. Large phase III multi-centre RCT of NDO pts with MS and SCI showing good efficacy of 200 and 300 U OnabotulinumtoxinA.. CrossRef
- Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2013. doi:10.1002/nau.22376.
- Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229–35. CrossRef
- Deffontaines-Rufin S, Weil M, Verollet D, Peyrat L, Amarenco G. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients. Int Braz J Urol. 2011;37(5):642–8. CrossRef
- • Kennelly M, Dmochowski R, Ethans K, Karsenty G, Schulte-Baukloh H, Jenkins B, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence Due to neurogenic detrusor overactivity: an interim analysis. Urology. 2013;81(3):491–7. Efficacy of repeated injections of BTX-A in NDO patients.. CrossRef
- Hikita K, Honda M, Kawamoto B, Panagiota T, Inoue S, Hinata N, et al. Botulinum toxin type A injection for neurogenic detrusor overactivity: clinical outcome in Japanese patients. Int J Urol. 2013;20(1):94–9. CrossRef
- Khan S, Game X, Kalsi V, Gonzales G, Panicker J, Elneil S, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185(4):1344–9. CrossRef
- Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, et al. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol. 2011;186(3):960–4. CrossRef
- Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32(3):242–9.
- Kuo HC, Liu SH. Effect of repeated detrusor onabotulinumtoxinA injections on bladder and renal function in patients with chronic spinal cord injuries. Neurourol Urodyn. 2011;30(8):1541–5. CrossRef
- Jia C, Liao LM, Chen G, Sui Y. Detrusor botulinum toxin A injection significantly decreased urinary tract infection in patients with traumatic spinal cord injury. Spinal Cord. 2013. doi:10.1038/sc.2012.180.
- • Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C et al. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase III Randomized Placebo-Controlled Trial. J Urol. 2012. doi:10.1016/j.juro.2012.12.022. Large phase III RCT assessing OnabotulinumtoxinA at 100 U verus placebo.
- Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, et al. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803–13. CrossRef
- Fowler CJ, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012;62(1):148–57. CrossRef
- Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011;30(4):556–62. CrossRef
- Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol. 2012;62(3):507–14. CrossRef
- Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol. 2012;61(4):834–9. CrossRef
- Game X, Khan S, Panicker JN, Kalsi V, Dalton C, Elneil S, et al. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity. BJU Int. 2011;107(11):1786–92. CrossRef
- Granese R, Adile G, Gugliotta G, Cucinella G, Saitta S, Adile B. Botox((R)) for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection. Arch Gynecol Obstet. 2012;286(4):923–9. CrossRef
- Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111(1):106–13. CrossRef
- Sahai A, Kalsi V, Khan MS, Fowler CJ. Techniques for the intradetrusor administration of botulinum toxin. BJU Int. 2006;97(4):675–8. CrossRef
- Manecksha RP, Cullen IM, Ahmad S, McNeill G, Flynn R, McDermott TE, et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol. 2012;61(5):928–35. CrossRef
- Alloussi SH, Lang C, Eichel R, Al-Kaabneh A, Seibold J, Schwentner C, et al. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment. World J Urol. 2012;30(3):367–73. CrossRef
- Krhut J, Samal V, Nemec D, Zvara P. Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord. 2012;50(12):904–7. CrossRef
- • Kuo H-C. Bladder base/trigone injection is safe and as effective as bladder body injection of OnabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30(7):1242–8. Open label study assessing different BTX-A injection techniques in the bladder..
- Padmanabhan P, Scarpero HM, Milam DF, Dmochowski RR, Penson DF. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urol. 2011;29(1):51–7. CrossRef
- Leong RK, de Wachter SG, Joore MA, van Kerrebroeck PE. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int. 2011;108(4):558–64. CrossRef
- Arlandis S, Castro D, Errando C, Fernandez E, Jimenez M, Gonzalez P, et al. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. Value Health. 2011;14(2):219–28. CrossRef
- Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003;62(2):259–64. discussion 64-5. CrossRef
- Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT, et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol. 2011;186(3):965–70. CrossRef
- Arnouk R, Suzuki Bellucci CH, Benatuil Stull R, de Bessa Jr J, Malave CA, Mendes Gomes C. Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. Sci World J. 2012;2012:463574. doi:10.1100/2012/463574. CrossRef
- de Kort LM, Kok ET, Jonges TN, Rosier PF, Bosch JL. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia. Urology. 2012;80(4):889–93. CrossRef
- Sacco E, Bientinesi R, Marangi F, Totaro A, D'Addessi A, Racioppi M, et al. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study. BJU Int. 2012;110(11 Pt C):E837–44. CrossRef
- Hamidi Madani A, Enshaei A, Heidarzadeh A, Mokhtari G, Farzan A, Mohiti Asli M, et al. Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates. World J Urol. 2013;31(1):235–9. CrossRef
- • Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, et al. A randomized double-blind placebo-controlled phase II dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol. 2013;63(3):496–503. Largest RCT assessing BTX-A injections vs placebo into the prostate for BPH.. CrossRef
- Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Silva C, et al. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int. 2011;107(12):1950–4. CrossRef
- van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7. CrossRef
- Giannantoni A, Bini V, Dmochowski R, Hanno P, Nickel JC, Proietti S, et al. Contemporary management of the painful bladder: a systematic review. Eur Urol. 2012;61(1):29–53. CrossRef
- Gottsch HP, Miller JL, Yang CC, Berger RE. A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome. Neurourol Urodyn. 2011;30(1):93–6. CrossRef
- Chung SD, Kuo YC, Kuo HC. Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Phys. 2012;15(3):197–202.
- Pinto R, Lopes T, Silva J, Silva C, Dinis P, Cruz F. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. J Urol. 2013;189(2):548–53. CrossRef
- Botulinum Toxin—What Urologic Uses Does the Data Support?
Current Urology Reports
Volume 14, Issue 3 , pp 227-234
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Detrusor overactivity
- Overactive bladder
- Painful bladder syndrome
- Interstitial cystitis
- Benign prostatic hyperplasia
- Botulinum toxin A
- Industry Sectors
- Author Affiliations
- 1. Department of Uro-Neurology, UCL Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK
- 2. MRC Centre for Transplantation, King’s College London, King’s Health Partners, Department of Urology, Guy’s Hospital, London, SE1 9RT, UK